This document is a publication of a European patent (EP4509173A2) granted to Kissei Pharmaceutical Co., Ltd. The patent covers specific dosing regimens for Gonadotropin-Releasing Hormone (GnRH) antagonists aimed at treating uterine fibroids and reducing associated menstrual blood loss. The publication date is March 18, 2026.

As this is a patent publication, it does not impose direct compliance obligations on regulated entities. However, it is relevant for pharmaceutical companies and healthcare providers involved in the research, development, or commercialization of treatments for uterine fibroids. Companies operating in this therapeutic area should be aware of the patent's existence and scope as it pertains to intellectual property rights.